BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 30942425)

  • 1. miR‑802 inhibits the aggressive behaviors of non‑small cell lung cancer cells by directly targeting FGFR1.
    Zhang J; Li J; Li S; Zhou C; Qin Y; Li X
    Int J Oncol; 2019 Jun; 54(6):2211-2221. PubMed ID: 30942425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-379 acts as a tumor suppressor in non-small cell lung cancer by targeting the IGF‑1R-mediated AKT and ERK pathways.
    Zhou F; Nie L; Feng D; Guo S; Luo R
    Oncol Rep; 2017 Sep; 38(3):1857-1866. PubMed ID: 28731178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sirtuin 7 promotes non‑small cell lung cancer progression by facilitating G1/S phase and epithelial‑mesenchymal transition and activating AKT and ERK1/2 signaling.
    Zhao Y; Ye X; Chen R; Gao Q; Zhao D; Ling C; Qian Y; Xu C; Tao M; Xie Y
    Oncol Rep; 2020 Sep; 44(3):959-972. PubMed ID: 32705247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis.
    Lu C; Shan Z; Hong J; Yang L
    Int J Oncol; 2017 Jul; 51(1):235-244. PubMed ID: 28534966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SIRT6 through PI3K/Akt/mTOR signaling pathway to enhance radiosensitivity of non-Small cell lung cancer and inhibit tumor progression.
    Xiong L; Tan B; Lei X; Zhang B; Li W; Liu D; Xia T
    IUBMB Life; 2021 Sep; 73(9):1092-1102. PubMed ID: 34033225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-107 inhibits tumor growth and metastasis by targeting the BDNF-mediated PI3K/AKT pathway in human non-small lung cancer.
    Xia H; Li Y; Lv X
    Int J Oncol; 2016 Oct; 49(4):1325-33. PubMed ID: 27498977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting SNORA38B attenuates tumorigenesis and sensitizes immune checkpoint blockade in non-small cell lung cancer by remodeling the tumor microenvironment via regulation of GAB2/AKT/mTOR signaling pathway.
    Zhuo Y; Li S; Hu W; Zhang Y; Shi Y; Zhang F; Zhang J; Wang J; Liao M; Chen J; Qian H; Li D; Sun C
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35577506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. microRNA-935 is reduced in non-small cell lung cancer tissue, is linked to poor outcome, and acts on signal transduction mediator E2F7 and the AKT pathway.
    Wang C; Li S; Xu J; Niu W; Li S
    Br J Biomed Sci; 2019 Jan; 76(1):17-23. PubMed ID: 30203720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PTPRH promotes the progression of non-small cell lung cancer via glycolysis mediated by the PI3K/AKT/mTOR signaling pathway.
    Wang S; Cheng Z; Cui Y; Xu S; Luan Q; Jing S; Du B; Li X; Li Y
    J Transl Med; 2023 Nov; 21(1):819. PubMed ID: 37974250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-625 inhibits the progression of non‑small cell lung cancer by directly targeting HOXB5 and deactivating the Wnt/β-catenin pathway.
    Tan X; Jiang L; Wu X; Feng W; Lin Q
    Int J Mol Med; 2019 Jul; 44(1):346-356. PubMed ID: 31115501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FAM83D promotes epithelial-mesenchymal transition, invasion and cisplatin resistance through regulating the AKT/mTOR pathway in non-small-cell lung cancer.
    Yin C; Lin X; Wang Y; Liu X; Xiao Y; Liu J; Snijders AM; Wei G; Mao JH; Zhang P
    Cell Oncol (Dordr); 2020 Jun; 43(3):395-407. PubMed ID: 32006253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hsa_circ_0016760 exacerbates the malignant development of non‑small cell lung cancer by sponging miR‑145‑5p/FGF5.
    Zhu Z; Wu Q; Zhang M; Tong J; Zhong B; Yuan K
    Oncol Rep; 2021 Feb; 45(2):501-512. PubMed ID: 33416186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long noncoding RNA OSER1‑AS1 promotes the malignant properties of non‑small cell lung cancer by sponging microRNA‑433‑3p and thereby increasing Smad2 expression.
    Liu X; Huang S; Guan Y; Zhang Q
    Oncol Rep; 2020 Aug; 44(2):599-610. PubMed ID: 32627026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardamonin inhibits the proliferation and metastasis of non-small-cell lung cancer cells by suppressing the PI3K/Akt/mTOR pathway.
    Zhou X; Zhou R; Li Q; Jie X; Hong J; Zong Y; Dong X; Zhang S; Li Z; Wu G
    Anticancer Drugs; 2019 Mar; 30(3):241-250. PubMed ID: 30640793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LncRNA MALAT1 promotes migration and invasion of non-small-cell lung cancer by targeting miR-206 and activating Akt/mTOR signaling.
    Tang Y; Xiao G; Chen Y; Deng Y
    Anticancer Drugs; 2018 Sep; 29(8):725-735. PubMed ID: 29916897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR‑505 inhibits cell growth and EMT by targeting MAP3K3 through the AKT‑NFκB pathway in NSCLC cells.
    Tang H; Lv W; Sun W; Bi Q; Hao Y
    Int J Mol Med; 2019 Mar; 43(3):1203-1216. PubMed ID: 30628663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FKBP4 Accelerates Malignant Progression of Non-Small-Cell Lung Cancer by Activating the Akt/mTOR Signaling Pathway.
    Meng W; Meng J; Jiang H; Feng X; Wei D; Ding Q
    Anal Cell Pathol (Amst); 2020; 2020():6021602. PubMed ID: 33354489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-198 inhibits proliferation and induces apoptosis of lung cancer cells via targeting FGFR1.
    Yang J; Zhao H; Xin Y; Fan L
    J Cell Biochem; 2014 May; 115(5):987-95. PubMed ID: 24357456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of microRNA-135a on Cell Proliferation, Migration, Invasion, Apoptosis and Tumor Angiogenesis Through the IGF-1/PI3K/Akt Signaling Pathway in Non-Small Cell Lung Cancer.
    Zhou Y; Li S; Li J; Wang D; Li Q
    Cell Physiol Biochem; 2017; 42(4):1431-1446. PubMed ID: 28715819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long Noncoding RNA SNHG6 Promotes Proliferation and Inhibits Apoptosis in Non-small Cell Lung Cancer Cells by Regulating miR-490-3p/RSF1 Axis.
    Dong Z; Liu H; Zhao G
    Cancer Biother Radiopharm; 2020 Jun; 35(5):351-361. PubMed ID: 32202941
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.